Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …

Several cancer treatments are shifting from traditional, time-limited, nonspecific cytotoxic
chemotherapy cycles to continuous oral treatment with specific protein-targeted therapies. In …

Herpesvirus Infections Potentiated by Biologics - Infectious Disease Clinics Skip to Main Content
Advertisement Infectious Disease Clinics Log in Register Log in Subscribe Claim Skip menu …

Imatinib mesylate (Gleevec™) is widely-used in the treatment of chronic myeloid leukaemia
(CML) and gastrointestinal stromal tumour. Up to four percent of patients treated with …

Hepatitis B virus (HBV) reactivation is a known risk in cancer patients receiving cytotoxic or
immunosuppressive therapy; however, the risk associated with newer molecularly-targeted …

The introduction of BCR-ABL-tyrosine kinase inhibitors (TKI) for treatment of hematologic
malignancies has made a significant impact on patient outcome. Contingent upon their …

BACKGROUND: Gastrointestinal stromal tumour (GIST) represents only 1% of all malignant
tumours of the gastrointestinal tract (GIT) but it is the most common gastrointestinal …

Background: Imatinib mesylate (IM) is the standard treatment for BCR-ABL-positive chronic
myelogenous leukemia (CML) and is the first-line adjuvant and palliative treatment for …

Background: To assess the response and the impact on the overall survival (OS) on c-KIT-
positive (CD117+) gastrointestinal stromal tumours (GISTs) patients treated with imatinib …

In vitro studies have shown possible antiviral effects of tyrosine kinase inhibitors. In a
retrospective study, we show that use of the tyrosine kinase inhibitor imatinib does not …